Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma

Anne Stone, Danielle Novetsky Friedman, Stefan Worgall, Brian H. Kushner, Suzanne Wolden, Shakeel Modak, Michael P. LaQuaglia, Xian Wu, Nai Kong Cheung, Charles A. Sklar

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Children with high-risk neuroblastoma are exposed to multimodality therapies early in life and survivors confront late therapy-related toxicities. This study assessed respiratory symptoms, pulmonary function tests (PFTs), and risk factors for abnormalities among survivors. Materials and Methods: High-risk neuroblastoma survivors followed in the long-term follow-up clinic at Memorial Sloan Kettering Cancer Center were enrolled. Self-administered symptom questionnaires were completed. Medical records were reviewed for treatment information and comorbidities. PFTs included spirometry, plethysmography, and diffusion capacity of the lung for carbon monoxide (DLCO). Results: Thirty-nine survivors participated (median age at study: 11.4 y; median age at diagnosis: 2.3 y; median time since completion of therapy: 5.5 y). Chronic respiratory symptoms were reported for 33%. PFT abnormalities were identified in 79% and included low forced expiratory volume in 1 second (38%), decreased total lung capacity (44%), and abnormal DLCO (67%). PFT abnormalities were mostly mild to moderate. Mean forced vital capacity, forced expiratory volume in 1 second, and total lung capacity were normal and mean DLCO was mildly abnormal. Risks included thoracic surgery, chest radiation therapy, thoracic surgery plus chest radiation therapy, and shorter time since completion of therapy (P<0.05). Conclusions: Although respiratory abnormalities were common, they were mostly mild or moderate. Continued pulmonary surveillance of this at-risk population is warranted.

Original languageEnglish (US)
Pages (from-to)547-554
Number of pages8
JournalJournal of Pediatric Hematology/Oncology
Volume39
Issue number7
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Neuroblastoma
Respiratory Function Tests
Pediatrics
Lung
Total Lung Capacity
Forced Expiratory Volume
Thoracic Surgery
Radiotherapy
Thorax
Lung Volume Measurements
Therapeutics
Plethysmography
Spirometry
Vital Capacity
Carbon Monoxide
Medical Records
Comorbidity
Neoplasms

Keywords

  • antineoplastic therapy
  • neuroblastoma
  • pulmonary function tests
  • respiratory symptoms
  • risk factors
  • survivors

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Stone, A., Friedman, D. N., Worgall, S., Kushner, B. H., Wolden, S., Modak, S., ... Sklar, C. A. (2017). Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma. Journal of Pediatric Hematology/Oncology, 39(7), 547-554. https://doi.org/10.1097/MPH.0000000000000883

Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma. / Stone, Anne; Friedman, Danielle Novetsky; Worgall, Stefan; Kushner, Brian H.; Wolden, Suzanne; Modak, Shakeel; LaQuaglia, Michael P.; Wu, Xian; Cheung, Nai Kong; Sklar, Charles A.

In: Journal of Pediatric Hematology/Oncology, Vol. 39, No. 7, 01.01.2017, p. 547-554.

Research output: Contribution to journalArticle

Stone, A, Friedman, DN, Worgall, S, Kushner, BH, Wolden, S, Modak, S, LaQuaglia, MP, Wu, X, Cheung, NK & Sklar, CA 2017, 'Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma', Journal of Pediatric Hematology/Oncology, vol. 39, no. 7, pp. 547-554. https://doi.org/10.1097/MPH.0000000000000883
Stone, Anne ; Friedman, Danielle Novetsky ; Worgall, Stefan ; Kushner, Brian H. ; Wolden, Suzanne ; Modak, Shakeel ; LaQuaglia, Michael P. ; Wu, Xian ; Cheung, Nai Kong ; Sklar, Charles A. / Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma. In: Journal of Pediatric Hematology/Oncology. 2017 ; Vol. 39, No. 7. pp. 547-554.
@article{917d913b12d448f1ba32f1e5357e6f95,
title = "Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma",
abstract = "Background: Children with high-risk neuroblastoma are exposed to multimodality therapies early in life and survivors confront late therapy-related toxicities. This study assessed respiratory symptoms, pulmonary function tests (PFTs), and risk factors for abnormalities among survivors. Materials and Methods: High-risk neuroblastoma survivors followed in the long-term follow-up clinic at Memorial Sloan Kettering Cancer Center were enrolled. Self-administered symptom questionnaires were completed. Medical records were reviewed for treatment information and comorbidities. PFTs included spirometry, plethysmography, and diffusion capacity of the lung for carbon monoxide (DLCO). Results: Thirty-nine survivors participated (median age at study: 11.4 y; median age at diagnosis: 2.3 y; median time since completion of therapy: 5.5 y). Chronic respiratory symptoms were reported for 33{\%}. PFT abnormalities were identified in 79{\%} and included low forced expiratory volume in 1 second (38{\%}), decreased total lung capacity (44{\%}), and abnormal DLCO (67{\%}). PFT abnormalities were mostly mild to moderate. Mean forced vital capacity, forced expiratory volume in 1 second, and total lung capacity were normal and mean DLCO was mildly abnormal. Risks included thoracic surgery, chest radiation therapy, thoracic surgery plus chest radiation therapy, and shorter time since completion of therapy (P<0.05). Conclusions: Although respiratory abnormalities were common, they were mostly mild or moderate. Continued pulmonary surveillance of this at-risk population is warranted.",
keywords = "antineoplastic therapy, neuroblastoma, pulmonary function tests, respiratory symptoms, risk factors, survivors",
author = "Anne Stone and Friedman, {Danielle Novetsky} and Stefan Worgall and Kushner, {Brian H.} and Suzanne Wolden and Shakeel Modak and LaQuaglia, {Michael P.} and Xian Wu and Cheung, {Nai Kong} and Sklar, {Charles A.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/MPH.0000000000000883",
language = "English (US)",
volume = "39",
pages = "547--554",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma

AU - Stone, Anne

AU - Friedman, Danielle Novetsky

AU - Worgall, Stefan

AU - Kushner, Brian H.

AU - Wolden, Suzanne

AU - Modak, Shakeel

AU - LaQuaglia, Michael P.

AU - Wu, Xian

AU - Cheung, Nai Kong

AU - Sklar, Charles A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Children with high-risk neuroblastoma are exposed to multimodality therapies early in life and survivors confront late therapy-related toxicities. This study assessed respiratory symptoms, pulmonary function tests (PFTs), and risk factors for abnormalities among survivors. Materials and Methods: High-risk neuroblastoma survivors followed in the long-term follow-up clinic at Memorial Sloan Kettering Cancer Center were enrolled. Self-administered symptom questionnaires were completed. Medical records were reviewed for treatment information and comorbidities. PFTs included spirometry, plethysmography, and diffusion capacity of the lung for carbon monoxide (DLCO). Results: Thirty-nine survivors participated (median age at study: 11.4 y; median age at diagnosis: 2.3 y; median time since completion of therapy: 5.5 y). Chronic respiratory symptoms were reported for 33%. PFT abnormalities were identified in 79% and included low forced expiratory volume in 1 second (38%), decreased total lung capacity (44%), and abnormal DLCO (67%). PFT abnormalities were mostly mild to moderate. Mean forced vital capacity, forced expiratory volume in 1 second, and total lung capacity were normal and mean DLCO was mildly abnormal. Risks included thoracic surgery, chest radiation therapy, thoracic surgery plus chest radiation therapy, and shorter time since completion of therapy (P<0.05). Conclusions: Although respiratory abnormalities were common, they were mostly mild or moderate. Continued pulmonary surveillance of this at-risk population is warranted.

AB - Background: Children with high-risk neuroblastoma are exposed to multimodality therapies early in life and survivors confront late therapy-related toxicities. This study assessed respiratory symptoms, pulmonary function tests (PFTs), and risk factors for abnormalities among survivors. Materials and Methods: High-risk neuroblastoma survivors followed in the long-term follow-up clinic at Memorial Sloan Kettering Cancer Center were enrolled. Self-administered symptom questionnaires were completed. Medical records were reviewed for treatment information and comorbidities. PFTs included spirometry, plethysmography, and diffusion capacity of the lung for carbon monoxide (DLCO). Results: Thirty-nine survivors participated (median age at study: 11.4 y; median age at diagnosis: 2.3 y; median time since completion of therapy: 5.5 y). Chronic respiratory symptoms were reported for 33%. PFT abnormalities were identified in 79% and included low forced expiratory volume in 1 second (38%), decreased total lung capacity (44%), and abnormal DLCO (67%). PFT abnormalities were mostly mild to moderate. Mean forced vital capacity, forced expiratory volume in 1 second, and total lung capacity were normal and mean DLCO was mildly abnormal. Risks included thoracic surgery, chest radiation therapy, thoracic surgery plus chest radiation therapy, and shorter time since completion of therapy (P<0.05). Conclusions: Although respiratory abnormalities were common, they were mostly mild or moderate. Continued pulmonary surveillance of this at-risk population is warranted.

KW - antineoplastic therapy

KW - neuroblastoma

KW - pulmonary function tests

KW - respiratory symptoms

KW - risk factors

KW - survivors

UR - http://www.scopus.com/inward/record.url?scp=85022176692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022176692&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000000883

DO - 10.1097/MPH.0000000000000883

M3 - Article

C2 - 28692550

AN - SCOPUS:85022176692

VL - 39

SP - 547

EP - 554

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 7

ER -